Interim analysis of ChronSeal®

In the recently conducted interim analysis of the phase I/IIa study on the wound healing product ChronSeal® in which Tripep has a 10% ownership it was concluded that the group of patients randomized for placebo treatment but receiving standard of care at the time of the analysis was too small for allowing statistical analysis. The trends that could be drawn were so encouraging that the study will continue and thereby be expanded by 50% of the study population size at the time of the interim analysis. Also so far the study has shown that ChronSeal® is safe and that no serious or unexpected side effects have been reported. The final results are estimated to be obtained already during the first quarter of 2010. For more information, please contact: Anders Vahlne, CEO & Head of Research, Tripep AB Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@ki.se About Tripep Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website: www.tripep.se. In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.